Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Osteoporosis 5Prostatic Neoplasms 3Breast Neoplasms 3Hypogonadism 2Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Genetic Diseases, Inborn 1

Interventions

pembrolizumab 156Gemcitabine 139Capecitabine 121Paclitaxel 119Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 93Cisplatin 90Irinotecan 88Carboplatin 85Radiosurgery 83Cyclophosphamide 71Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 46Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × Alendronate × Clear all
NCT00019695 2024-03-04

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
Genitourinary

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms, Genetic Diseases, Inborn

Data powered by HemOnc (CC BY 4.0) Colophon âš¡